H. Daniel Perez, MD, a Venture Partner with Bay City Capital since 2007, was previously President and CEO of Berlex (the US arm of Schering AG) where he led the company's R&D efforts in the US and overseas, initiated multiple human clinical trials, and oversaw the execution of numerous collaborations, licensing deals, spin-outs and acquisitions, until leaving the company in 2006 upon its acquisition by Bayer. Dr. Perez is on the Board of Directors of Presidio Pharmaceuticals and Celtaxys, and serves on the Scientific Advisory Boards of Cardium and Vertex Pharmaceuticals.  He is also a member of the Investment Board of GSK, China, and the President's Council for the Gladstone Institutes at the University of California, San Francisco (UCSF).  He was a member of the Board of Directors of BayBio, Cleveland Biolabs and Hyperion Therapeutics.  Dr. Perez received his medical degree in Buenos Aires, Argentina and completed his medical training at Beth Israel-Mount Sinai in New York City, as well as a fellowship in rhematology and immunology at NYU. He joined the faculty at NYU as an Assistant Professor of Medicine and was a Professor of Medicine at UCSF until 1993. Dr. Perez has published extensively, has been elected to multiple scientific societies and nominated to the National Academy of Sciences.